ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China
August 05, 2021Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced today that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong, S.A.R., China and Macau, S.A -
Rigel & Kissei Enter Agreement
October 30, 2018Rigel & Kissei Enter Agreement
Pharma Sources Insight January 2025
